{"title":"Testing psychosocial interventions in the contexts they are meant to be delivered.","authors":"Rinad S Beidas, Lisa Saldana, Rachel C Shelton","doi":"10.1037/ccp0000797","DOIUrl":null,"url":null,"abstract":"<p><p>This article discusses psychosocial interventions in the contexts they are meant to be delivered. Prevention and intervention science often follow the linear pathway of preclinical or pre-intervention research-efficacy trials, effectiveness trials, and implementation studies-with the assessment of translation into public and population health impact occurring at the end. This linear translational pathway follows stages developed for ascertaining safe, efficacious, and effective dosages for biological compounds. This approach has created limitations in the need to rapidly deploy complex, multi-component, multilevel approaches to change behavior and improve health into widespread practice for diverse clinical and public health settings. While it is important to use efficacy trials when safety is yet to be established, when the risks are identified to be low, as is often the case for psychosocial interventions, we can go faster to achieve equitable population health impact. The authors recommend that clinical trialists engaged in intervention development incorporate two considerations in the next generation of prevention and intervention research. First, consider moving right to effectiveness or pragmatic trials, as the most valid test of an intervention is the est of that intervention in the context(s) in which it is intended. Second, when designing effectiveness studies, consider investigating questions related to both effectiveness (i.e., does the intervention improve clinical outcomes) and implementation (i.e., what supports are needed to deploy the intervention routinely in that context) to accelerate impact. As a matter of both ethics and equity, there is a need to expedite the research-to-practice pipeline at a pace faster than is made available through current approaches. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</p>","PeriodicalId":15447,"journal":{"name":"Journal of consulting and clinical psychology","volume":"91 4","pages":"189-191"},"PeriodicalIF":4.5000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of consulting and clinical psychology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1037/ccp0000797","RegionNum":1,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
This article discusses psychosocial interventions in the contexts they are meant to be delivered. Prevention and intervention science often follow the linear pathway of preclinical or pre-intervention research-efficacy trials, effectiveness trials, and implementation studies-with the assessment of translation into public and population health impact occurring at the end. This linear translational pathway follows stages developed for ascertaining safe, efficacious, and effective dosages for biological compounds. This approach has created limitations in the need to rapidly deploy complex, multi-component, multilevel approaches to change behavior and improve health into widespread practice for diverse clinical and public health settings. While it is important to use efficacy trials when safety is yet to be established, when the risks are identified to be low, as is often the case for psychosocial interventions, we can go faster to achieve equitable population health impact. The authors recommend that clinical trialists engaged in intervention development incorporate two considerations in the next generation of prevention and intervention research. First, consider moving right to effectiveness or pragmatic trials, as the most valid test of an intervention is the est of that intervention in the context(s) in which it is intended. Second, when designing effectiveness studies, consider investigating questions related to both effectiveness (i.e., does the intervention improve clinical outcomes) and implementation (i.e., what supports are needed to deploy the intervention routinely in that context) to accelerate impact. As a matter of both ethics and equity, there is a need to expedite the research-to-practice pipeline at a pace faster than is made available through current approaches. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
本文讨论的是社会心理干预措施的实施背景。预防和干预科学通常遵循临床前或干预前研究--功效试验、有效性试验和实施研究--的线性路径,最后评估转化为对公众和人口健康的影响。这种线性转化途径遵循为确定生物化合物的安全、有效剂量而开发的各个阶段。由于需要快速部署复杂、多成分、多层次的方法来改变行为和改善健康,并将其广泛应用于不同的临床和公共卫生环境,这种方法造成了局限性。在安全性尚未确定的情况下,使用疗效试验固然重要,但当风险被确定为较低时,就像社会心理干预通常的情况一样,我们可以更快地实现公平的人群健康影响。作者建议参与干预措施开发的临床试验人员在下一代预防和干预研究中考虑两个因素。首先,考虑直接进行有效性或实用性试验,因为对干预措施最有效的检验是干预措施在预期环境中的效果。其次,在设计有效性研究时,应考虑调查与有效性(即干预措施是否能改善临床结果)和实施(即在这种情况下常规部署干预措施需要哪些支持)相关的问题,以加快产生影响。从伦理和公平的角度考虑,有必要加快从研究到实践的进程,其速度应快于目前的方法。(PsycInfo Database Record (c) 2023 APA, all rights reserved)。
期刊介绍:
The Journal of Consulting and Clinical Psychology® (JCCP) publishes original contributions on the following topics: the development, validity, and use of techniques of diagnosis and treatment of disordered behaviorstudies of a variety of populations that have clinical interest, including but not limited to medical patients, ethnic minorities, persons with serious mental illness, and community samplesstudies that have a cross-cultural or demographic focus and are of interest for treating behavior disordersstudies of personality and of its assessment and development where these have a clear bearing on problems of clinical dysfunction and treatmentstudies of gender, ethnicity, or sexual orientation that have a clear bearing on diagnosis, assessment, and treatmentstudies of psychosocial aspects of health behaviors. Studies that focus on populations that fall anywhere within the lifespan are considered. JCCP welcomes submissions on treatment and prevention in all areas of clinical and clinical–health psychology and especially on topics that appeal to a broad clinical–scientist and practitioner audience. JCCP encourages the submission of theory–based interventions, studies that investigate mechanisms of change, and studies of the effectiveness of treatments in real-world settings. JCCP recommends that authors of clinical trials pre-register their studies with an appropriate clinical trial registry (e.g., ClinicalTrials.gov, ClinicalTrialsRegister.eu) though both registered and unregistered trials will continue to be considered at this time.